Johnson & Johnson

Latest Headlines

Latest Headlines

California goes after Purdue, Endo, J&J, Actavis and Teva over opioids

California has decided to lay the responsibility for opioid overdoses, and even a resurgence in heroin use, at the feet of the drugmakers, accusing them in a lawsuit of reaping huge profits while turning a large swath of people into drug addicts.

J&J: Expect more consolidation in orthopedics industry

Michael Orsinger, chairman of Johnson & Johnson's DePuy Synthes orthopedics unit, said May 22 that customers are demanding a "one stop shop" approach toward implants, predicting that it will drive continued consolidation in the industry.

Need a job? J&J, Novartis and Biogen Idec are pharma's favorite employers

With all of the pharma layoffs, lots of folks are looking for a job in the industry. So where are the best places to work? Johnson & Johnson and Novartis if you want to work for a large company. Biogen Idec, Gilead or perhaps Novo Nordisk if you prefer more of a midsize drugmaker.

J&J's new incubator opens its arms to med tech startups

Janssen, the biotech unit of Johnson & Johnson, is looking beyond just pharmaceuticals with its latest life sciences incubator, seeking out medical device and diagnostics startups to fill its planned lab space.

J&J scouts for 50 Bay biotechs with new Janssen incubator

Johnson & Johnson's Janssen arm is planning to open another biotech incubator, this time setting its sights on South San Francisco in hopes of finding a few promising drug developers.

FDA finds Boehringer Ingelheim's Pradaxa safer than warfarin in most ways

It turns out that Boehringer Ingelheim's popular anticoagulant Pradaxa is safer than many people think. That is the finding of the FDA after taking another look at the side effects of the drug compared to the old standard warfarin and this time looking at a much larger and older patient base.

The top R&D spenders in biopharma in 2013

Over the past few years, the bottom-line number on R&D spending among the big 10 pharma companies--about $70 billion--has remained about the same. But behind the steady collective figure lies...

Cancer drugs from J&J, Roche, Celgene and more rival last big oncology wave

IMS Health has found that a group of cancer treatments launched over the past three years "are following the same trajectory" as blockbusters such as Roche's Avastin, Novartis' Gleevec, Bayer's Nexavar, and Merck Serono's Erbitux--at least so far.

J&J halts uterine device sales amid safety concerns

Weeks after the FDA warned of serious dangers tied to a surgical procedure to remove uterine fibroids, Johnson & Johnson is suspending sales of its related devices.

Allergan woos J&J, Sanofi while keeping its eyes on Shire, per reports

Allergan is keeping the M&A plates spinning amid Big Pharma's big embrace of megadeals, reportedly reaching out to potential suitors Sanofi and Johnson & Johnson while gearing up to make another pass at acquiring Shire.